Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.9412
Nov 17 • 8:39 AM ET Dollar change-0.0988 Percentage change(-9.50%)
Today, 12:15 AMXORTX Therapeutics reports fiscal Q3 2026 results with non-GAAP EPS $-0.21 (+68% YoY) and revenue $0
Index
-
Market Cap
1.71M
Enterprise Value
1.39M
Income
-3.47M
Sales
0.00M
Book/sh
2.69
Cash/sh
0.18
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
3
IPO
Nov 28, 2018
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.35
P/C
5.35
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
3.11
Current Ratio
3.11
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-2.29
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
51.52% 15.39%
Sales past 3/5Y
- -
EPS Y/Y TTM
2.68%
Sales Y/Y TTM
-
EPS Q/Q
68.29%
Sales Q/Q
-
Insider Own
7.84%
Insider Trans
0.00%
Inst Own
2.20%
Inst Trans
1.30%
ROA
-80.59%
ROE
-97.82%
ROIC
-67.75%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-3.34%
SMA50
-33.59%
SMA200
-53.41%
Trades
Shs Outstand
1.90M
Shs Float
1.67M
52W High
3.60 -73.86%
52W Low
0.82 15.47%
Volatility
29.46% 17.48%
ATR (14)
0.18
RSI (14)
40.22
Beta
0.78
Rel Volume
0.13
Avg Volume
762.28K
Volume
4,823
Perf Week
10.73%
Perf Month
-6.81%
Perf Quarter
-52.94%
Perf Half Y
-59.43%
Perf YTD
-66.51%
Perf Year
-64.88%
Perf 3Y
-93.73%
Perf 5Y
-99.23%
Perf 10Y
-
Prev Close
1.04
Price
0.94
Change %
-9.50%
XORTX Therapeutics, Inc. is a biopharmaceutical company. The firm engages in development and commercialization of innovative therapies. It focuses on drug therapies for rare orphan disease indications such as polycystic kidney disease, and the treatment of health consequences caused by chronic high serum uric acid or hyperuricemia, including Type 2 Diabetic Nephropathy, cardiovascular disease, and diabetes. The company was founded by Allen Davidoff on May 31, 2011 and is headquartered in Calgary, Canada.
FounderDr. Allen Warren Davidoff Ph.D.
M.B.A.Dr. Michael Scott Bumby D.V.M.
MRCPDr. Stephen Haworth M.D.
M.D.Dr. Stacy Evans M.B.A.
Co-CEO & DirectorMr. Mika Grasso